Last reviewed · How we verify
Dextromethorphan and quinidine
At a glance
| Generic name | Dextromethorphan and quinidine |
|---|---|
| Also known as | Nuedexta |
| Sponsor | Cady, Roger, M.D. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Imlunestrant (LY3484356) in Female Healthy Participants (PHASE1)
- Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (PHASE3)
- Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease (PHASE3)
- Impact of Nuedexta on Bulbar Physiology and Function in ALS (PHASE1, PHASE2)
- Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (PHASE3)
- Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type (PHASE3)
- Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients (PHASE2)
- A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dextromethorphan and quinidine CI brief — competitive landscape report
- Dextromethorphan and quinidine updates RSS · CI watch RSS
- Cady, Roger, M.D. portfolio CI